- Home
- STRW vs CGEN Comparison
STRW vs CGEN Comparison
Compare STRW & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- CGEN
- Stock Information
- Founded
- STRW 2015
- CGEN 1993
- Country
- STRW United States
- CGEN Israel
- Employees
- STRW N/A
- CGEN N/A
- Industry
- STRW Real Estate Investment Trusts
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STRW Real Estate
- CGEN Health Care
- Exchange
- STRW Nasdaq
- CGEN Nasdaq
- Market Cap
- STRW 133.6M
- CGEN 117.8M
- IPO Year
- STRW N/A
- CGEN 2000
- Fundamental
- Price
- STRW $10.20
- CGEN $1.47
- Analyst Decision
- STRW Strong Buy
- CGEN Strong Buy
- Analyst Count
- STRW 4
- CGEN 1
- Target Price
- STRW $13.83
- CGEN $4.00
- AVG Volume (30 Days)
- STRW 50.7K
- CGEN 216.5K
- Earning Date
- STRW 05-09-2025
- CGEN 05-19-2025
- Dividend Yield
- STRW 5.49%
- CGEN N/A
- EPS Growth
- STRW 34.22
- CGEN N/A
- EPS
- STRW 0.58
- CGEN N/A
- Revenue
- STRW $126,557,000.00
- CGEN $27,589,000.00
- Revenue This Year
- STRW $15.21
- CGEN $11.81
- Revenue Next Year
- STRW $2.21
- CGEN $28.37
- P/E Ratio
- STRW $17.69
- CGEN N/A
- Revenue Growth
- STRW 22.41
- CGEN N/A
- 52 Week Low
- STRW $8.70
- CGEN $1.13
- 52 Week High
- STRW $12.90
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- STRW 46.67
- CGEN 53.98
- Support Level
- STRW $9.46
- CGEN $1.38
- Resistance Level
- STRW $10.75
- CGEN $1.56
- Average True Range (ATR)
- STRW 0.66
- CGEN 0.08
- MACD
- STRW 0.03
- CGEN 0.02
- Stochastic Oscillator
- STRW 50.79
- CGEN 68.97
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.